Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.

• Status: Unknown status
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

1. Patients 18 years or above at the time of inclusion.

2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.

3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.

Exclusion Criteria:

1. Other types of non-Hodgkin lymphoma

2. Pregnancy and lactation.

3. Patient unable to give written informed consent.

4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.